Related Experiment Video

Updated: Jun 22, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Tyrosine kinases as targets for the treatment of rheumatoid arthritis

Christina D'Aura Swanson1, Ricardo T Paniagua, Tamsin M Lindstrom

  • 1Stanford University School of Medicine, Stanford, CA 94305, USA.

Nature Reviews. Rheumatology
|June 4, 2009
PubMed

Insights

Tyrosine kinases regulate cell signaling in rheumatoid arthritis (RA). Inhibiting these kinases may reduce inflammation and joint destruction characteristic of RA pathogenesis.

Area of Science:

  • Biochemistry
  • Immunology
  • Pathology

Background:

  • Tyrosine kinases are key regulators of cell signaling pathways.
  • Rheumatoid arthritis (RA) involves synovial inflammation and joint destruction.
  • Synoviocytes normally support cartilage, but proliferate in RA.

Purpose of the Study:

  • To explore the role of tyrosine kinases in rheumatoid arthritis pathogenesis.
  • To understand how tyrosine kinases contribute to synovial inflammation and joint damage in RA.

Main Methods:

  • Review of cell signaling pathways involving tyrosine kinases in RA.
  • Analysis of the role of inflammatory cell infiltration in RA synovium.
  • Examination of synoviocyte proliferation and pannus formation in RA.

Main Results:

  • Tyrosine kinases regulate critical cell responses in RA pathogenesis.
  • Inflammatory cells (macrophages, neutrophils, T cells, B cells) infiltrate RA synovium.
  • Pannus formation, driven by synoviocyte proliferation and inflammation, invades bone and cartilage.

Conclusions:

  • Tyrosine kinases are implicated in the development and progression of rheumatoid arthritis.
  • Targeting tyrosine kinases offers a potential therapeutic strategy for RA.
  • Inhibition of specific tyrosine kinases may alleviate RA-associated inflammation and joint destruction.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...